Deals
Ablynx Rises on Drug Licensing Deal With AbbVie: Brussels Mover
This article is for subscribers only.
Ablynx NV, a Belgian developer of an experimental drug against rheumatoid arthritis, rose to the highest price in more than two years after selling rights to the treatment to AbbVie Inc. for as much as $840 million.
Ablynx climbed 11 percent to 8.27 euros in Brussels, the highest since July 2011. More than 2.7 million shares were traded, the most since the company’s initial public offering in